Group 1 - The Shanghai Composite Index closed at 3844.84 points, above the five-day moving average, with a decline of 0.79% [1] - The total trading volume of A-shares reached 1,930.44 billion yuan [1] - A total of 299 A-shares have prices that surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] Group 2 - The stocks with the highest deviation rates from the five-day moving average include Haoer Sai (8.94%), Zhongyuan Home (8.75%), and Huadong CNC (8.29%) [1] - Other stocks that just crossed the five-day moving average include Knight Dairy, Mindong Power, and Bohai Ferry, which have smaller deviation rates [1] - The top stocks with significant price increases today include Haoer Sai (10.00%), Zhongyuan Home (9.97%), and Huadong CNC (10.02%) [1]

Core Viewpoint - The recent financial report of Weikang Pharmaceutical (300878) indicates a significant decline in revenue and profit, highlighting challenges in the company's business model and financial health [1][2]. Financial Performance Summary - As of the latest report, the total revenue is 115 million yuan, a year-on-year decrease of 61.42% [1]. - The net profit attributable to shareholders is -64.22 million yuan, reflecting a year-on-year decline of 552.5% [1]. - In the second quarter, total revenue was 44.79 million yuan, down 53.84% year-on-year, with a net profit of -54.36 million yuan, a decrease of 435.99% [1]. - The gross margin is reported at 21.77%, a drop of 57.76% compared to the previous year [1]. - The net margin stands at -56.13%, a significant decline of 1143.2% year-on-year [1]. - Total expenses (selling, administrative, and financial) reached 76.46 million yuan, accounting for 66.74% of total revenue, an increase of 53.54% year-on-year [1]. - Earnings per share are reported at -0.44 yuan, a decrease of 546.63% year-on-year [1]. Asset and Liability Overview - Cash and cash equivalents decreased to 273 million yuan, down 14.84% year-on-year [1]. - Accounts receivable fell to 114 million yuan, a decline of 56.57% [1]. - Interest-bearing liabilities decreased to 272 million yuan, down 20.35% year-on-year [1]. - The net asset value per share is reported at 7.41 yuan, a decrease of 18.58% [1]. Business Model Evaluation - The company's performance is primarily driven by marketing efforts, indicating a need for a deeper analysis of the underlying factors supporting this drive [2]. - Historical data shows a median Return on Invested Capital (ROIC) of 21.68%, with the worst year (2024) showing a ROIC of -8.38%, suggesting a fragile business model [2]. - The company has experienced two loss years since its listing, indicating potential vulnerabilities in its business operations [2].

Core Viewpoint - Weikang Pharmaceutical (300878) reported a revenue of 115 million yuan and a net profit of -64 million yuan for the first half of 2025, attributing the performance decline to reduced sales and the impact of subsidiary disposals from the previous year [1] Group 1: Financial Performance - In the first half of 2025, Weikang Pharmaceutical achieved a revenue of 115 million yuan, with a net profit of -64 million yuan [1] - The decline in performance is linked to a general slowdown in the pharmaceutical retail industry and the company's decision to optimize its business structure by divesting its wholly-owned subsidiary engaged in pharmaceutical retail [1] Group 2: R&D and Innovation - R&D capability is a core driver of Weikang Pharmaceutical's development, with the company appointing Nobel Prize winner Michael Levitt as chief scientist to enhance its R&D capabilities and international presence [2] - The company has established several high-level R&D platforms, including provincial high-tech enterprise research centers and expert workstations, to build a leading innovation system [2] - As of the report date, Weikang's Yipingfeng pill has received provincial high-tech product certification, and several other products have been recognized as provincial industrial new products [2] Group 3: Market Strategy and Product Development - Weikang Pharmaceutical is actively expanding into the traditional Chinese medicine health sector, particularly focusing on the market layout of Ganoderma lucidum spore powder and related products [2] - The company has established a high-standard quality system in its cultivation processes, achieving a 98% ultra-high breaking rate through low-temperature physical ultra-micro breaking technology, enhancing the bioavailability of active ingredients [3] - Weikang has engaged in strategic collaborations with well-known pharmacy enterprises to enhance brand market influence and terminal cooperation capabilities, laying a solid foundation for its second growth curve [3]

Core Viewpoint - Zhejiang Weikang Pharmaceutical Co., Ltd. reported a revenue of 115 million yuan and a net profit of -64 million yuan for the first half of 2025, attributing the performance decline to reduced sales and the previous year's subsidiary disposal [1] Group 1: Financial Performance - The company experienced a revenue of 115 million yuan and a net profit of -64 million yuan in the first half of 2025 [1] - The decline in performance is linked to a slowdown in the pharmaceutical retail industry and a strategic decision to optimize the business structure by divesting its wholly-owned subsidiary engaged in pharmaceutical retail [1] Group 2: R&D and Innovation - R&D capability is a core driving force for the company's development, with the appointment of Nobel Prize winner Michael Levitt as chief scientist to enhance R&D and internationalization [2] - The company has established several high-level R&D platforms, including provincial high-tech enterprise R&D centers and expert workstations, to build a leading innovation system [2] - The company’s products, such as Yipingfeng Granules and Fengliao Gastrointestinal Dispersible Tablets, have received provincial recognition, indicating effective market competitiveness [2] Group 3: Market Strategy and Product Development - The company is actively expanding into the traditional Chinese medicine health sector, focusing on the market layout of Ganoderma lucidum spore powder and developing a product line for future growth [2] - Utilizing the advantages of being located in "the first town of Ganoderma lucidum" in Longquan, Zhejiang, the company has established a high-standard quality system for cultivation [3] - The company has implemented a dual-channel sales strategy, combining online and offline efforts to enhance market penetration and sales volume [3] - Strategic partnerships with well-known pharmacy enterprises have been formed to enhance brand influence and terminal cooperation capabilities [3]

民生证券股份有限公司 关于浙江维康药业股份有限公司部分募集资金投资项目 延期的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为浙江 维康药业股份有限公司（以下简称"维康药业"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所创业板上市公司规范运作指引》及 《深圳证券交易所上市公司保荐工作指引》等有关规定，对公司部分募集资金投 资项目延期的事项进行了核查。 浙江维康药业股份有限公司于 2025 年 8 月 27 日召开第四届董事会第六次会 议、第四届监事会第六次会议，审议通过了《关于部分募集资金投资项目延期的 议案》，同意公司结合目前募集资金投资项目的实际进展情况，对募集资金投资 项目中的"营销网络中心建设项目"达到预定可使用状态的日期进行了延后调整， 具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江维康药业股份有限公司首次公开 发行股票注册的批复》（证监许可〔2020〕1652 号）同意注册， ...

非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2025年期初 | 2025半年度占用 累计发生金额 | 2025半年度占 用资金的利息 | 2025半年度偿 还累计发生金 | 2025半年度期末 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 占用资金余额 | （不含利息） | （如有） | 额 | 占用资金余额 | | | | 控股股东、实际控制人及其附 | | | | | | | | | | | | 属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其 | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 其他关联方及其附属企业 | ...

证券代码：300878 证券简称：维康药业 公告编号：2025-035 浙江维康药业股份有限公司 2025年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》和深圳证券交易所印发的《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》的规定，将本公司募集资 金 2025 年半年度存放与使用情况专项说明如下。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2020〕1652 号文核准，并经贵所同 意，本公司由主承销商民生证券股份有限公司采用网下向符合条件的网下投资者 询价配售与网上向持有深圳市场非限售 A 股股份和非限售存托凭证市值的社会 公众投资者定价发行相结合的方式，向社会公众公开发行人民币普通股（A 股） 股票 2,011.00 万股，每股发行价格为人民币 41.34 元，共计募集资金 83,134.74 万元，坐扣承销和保荐费用 7,215.86 万 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-036 浙江维康药业股份有限公司 关于部分募集资金投资项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于2025年8月27日召开第四届 董事会第六次会议、第四届监事会第六次会议，审议通过了《关于部分募集资金投 资项目延期的议案》，同意公司结合目前募集资金投资项目的实际进展情况，对募集 资金投资项目中的"营销网络中心建设项目"达到预定可使用状态的日期进行了延 后调整。保荐机构民生证券股份有限公司对本事项出具了表示同意的核查意见，本 次募投项目延期事项在董事会审批权限范围内，无需提交股东大会审议。现将相关 情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江维康药业股份有限公司首次公开发 行股票注册的批复》（证监许可〔2020〕1652号）同意注册，公司向社会公开发行人 民币普通股（A股）2,011万股，本次公开发行人民币普通股每股面值为人民币1.00元， 发行价格为41.34元/股，本次发行募集资金总额为83,134 ...

关于公司及子公司向银行申请授信额度及提供 抵押或质押担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、基本情况概述 2025 年 4 月 27 日，浙江维康药业股份有限公司（以下简称"公司"）召开第 四届董事会第五次会议、第四届监事会第五次会议，2025 年 5 月 20 日，公司召 开 2024 年度股东大会，审议通过了《关于公司及子公司 2025 年度向银行申请授 信额度及提供抵押或质押担保的议案》，同意公司及子公司 2025 年度向银行申 请综合授信额度不超过人民币 15 亿元（含到期后续授信），形式包括但不限于 流动资金贷款、固定资产贷款、项目贷款、承兑汇票、保函、开立信用证、票据 贴现等综合业务。公司及子公司办理融资业务时，可以以公司及子公司自有资产 进行抵押担保或质押担保。具体内容详见公司 2025 年 4 月 27 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于公司及子公司 2025 年度向银行申请授 信额度及提供抵押或质押担保的公告》（公告编号：2025-018）。 二、自有资产抵押进展情况 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-032 浙江维康药业股份有限公司 第四届监事会第六次会议决议公告 （二）审议通过《关于 2025 年半年度募集资金存放与使用情况的专项报告 的议案》 公司监事会审议通过了《公司 2025 年半年度募集资金存放与使用情况的专 项报告》 表决结果：3 票同意，0 票反对，0 票弃权。 （三）审议通过《关于部分募集资金投资项目延期的议案》 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）于 2025 年 8 月 17 日以电 子邮件、专人送达或电话方式发出第四届监事会第六次会议通知，会议于 2025 年 8 月 27 日在浙江省丽水经济开发区遂松路 2 号研发大楼二楼会议室以现场方 式召开，应参加表决的监事 3 人，实际参加表决的监事 3 人，会议由公司监事会 主席叶志学主持。本次会议的召集、召开和表决程序符合有关法律、法规、部门 规章、规范性文件和《公司章程》的规定，会议形成的决议合法有效。 二、监事会会议审议情况 （一）审议通过《关 ...